Physician profile
Diego O Munoz
NPI 1538399290
$16,804.94
in general payments reported to CMS, 2019-2025
35 companies · $3,405 in 2025
The $3,405 reported for 2025 was more than what 98% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,945 · 2020: $929 · 2021: $4,478 · 2022: $1,819 · 2023: $799 · 2024: $1,429 · 2025: $3,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,823 · Travel and Lodging: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,823.02 |
| Travel and Lodging | $810.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,783.26 | 2019-2025 | Fasenra |
| Janssen Pharmaceuticals, INC | $2,609.80 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,465.44 | 2019-2025 | Jardiance, Ofev |
| Penumbra, INC. | $1,317.49 | 2025 | Indigo System |
| Glaxosmithkline, LLC. | $1,267.29 | 2019-2025 | Arexvy, Nucala |
| Gilead Sciences, INC. | $966.99 | 2019-2025 | Trodelvy, Veklury |
| Novo Nordisk INC | $708.27 | 2019-2025 | Novoseven |
| Pfizer INC. | $584.96 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $575.80 | 2021-2025 | Zevtera, Xacduro |
| Abbvie INC. | $551.88 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $551.46 | 2019-2022 | |
| Genentech USA, INC. | $368.67 | 2019 | |
| Mylan Specialty L.P. | $248.52 | 2019-2021 | |
| Vifor Pharma, INC. | $243.40 | 2019-2021 | |
| Allergan, INC. | $222.54 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $220.59 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.86 | 2019-2025 | Lifevest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.19 | 2019 | |
| Abiomed | $125.00 | 2021 | |
| Paratek Pharmaceuticals, INC. | $125.00 | 2021 | |
| Incyte Corporation | $125.00 | 2025 | Zynyz |
| Medtronic, INC. | $124.99 | 2025 | Hawkone |
| Alkermes, INC. | $123.52 | 2021 | |
| Stemline Therapeutics INC. | $122.87 | 2025 | Orserdu |
| Novartis Pharmaceuticals Corporation | $122.70 | 2019 | |
| Boston Scientific Corporation | $121.34 | 2019 | |
| Genzyme Corporation | $120.91 | 2025 | |
| Celgene Corporation | $120.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $120.72 | 2024 | |
| Fisher Scientific Company L.L.C. | $113.11 | 2022 | |
| Esperion Therapeutics, INC. | $109.63 | 2021 | |
| Ekos Corporation | $93.35 | 2019 | |
| Lilly USA, LLC | $78.16 | 2019 | |
| Philips North America LLC | $71.41 | 2019 | |
| Shionogi INC | $25.97 | 2025 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.